News | October 18, 2023
Syngene Q2 FY23-24 revenue from operations up 18.5% to Rs 910 Cr
Profit after tax (before exceptional items) up 23% to Rs 215 crores
Profit after tax (before exceptional items) up 23% to Rs 215 crores
NexCAR19 is an indigenously developed CD19 targeted CAR-T cell therapy
Astria will assume full cost and responsibility for the global development and commercialization of the licensed therapeutic program for all indications
Expanding to states like Maharashtra, Andhra Pradesh, Telangana, and Manipur while marking the significant milestone in its journey towards providing accessible healthcare services
Biocon will be responsible for obtaining regulatory approval for Liraglutide, and thereafter, for the manufacture and supply of the product in the Canadian market
Lokavant provides clinical trial intelligence
VaxTRIALS Adds a New Latin America Base and Greater Vaccine Research Depth
This integrated care offering is a step forward in our vision of providing an effective continuum of care for patients
The AGE1.CR.pIX cell line's versatility allows it to support a wide range of viruses and vaccine types
India is promoting holistic healthcare with emphasis on preventive care
Subscribe To Our Newsletter & Stay Updated
